Vestal Point Capital, LP Aerovate Therapeutics, Inc. Transaction History

Vestal Point Capital, LP

  • $2.21 Trillion
  • Q3 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$9.58 - $24.25 $3.83 Million - $9.7 Million
400,000 New
400,000 $9.05 Billion

Others Institutions Holding AVTE

# of Institutions
3
Shares Held
1.63M
Call Options Held
0
Put Options Held
0
View Full List

About Aerovate Therapeutics, Inc.

AVTE Quotes by TradingView
  • Ticker AVTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,448,100
  • Market Cap $65.5M
  • Description
  • Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...
More about AVTE
Track This Portfolio

Track Vestal Point Capital, LP Portfolio

Follow Vestal Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestal Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Vestal Point Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email